- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
- Statistically Significant Reduction of 62% and 70% in Combined Unique Active Magnetic Resonance Imaging Lesions in 45mg and 30mg Patient Cohorts, As Compared to Placebo -
- Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -
- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -
- Conference Call and Webcast to be Held on August 3, 2020 at 8:30am ET -
PR Newswire
NEW YORK, Aug. 2, 2020